(Press-News.org) EVANSTON, Ill. --- Why do some people immediately burst into laughter after a humorous moment, while others can barely crack a smile? New research examining emotional reactivity suggests one of the answers may lie in a person's DNA.
In a new study linking a gene to positive emotional expressions such as smiling and laughing, researchers demonstrated that people with a certain genetic variant -- those with short alleles of the gene 5-HTTLPR -- smiled or laughed more while watching cartoons or subtly amusing film clips than people with long alleles.
Previous research has linked the gene to negative emotions; the study provides the strongest evidence to date that the same gene is also linked to positive emotional expressions.
The research will be published online June 1 in the American Psychological Association journal Emotion.
Claudia M. Haase of Northwestern University and Ursula Beermann of the University of Geneva co-authored the study, which was conducted in the laboratories of Dacher Keltner and Robert W. Levenson at the University of California, Berkeley.
In the study, the scientists looked at short and long alleles of the gene 5-HTTLPR, which is involved in the regulation of serotonin, a neurotransmitter implicated in depression and anxiety.
An allele is a variant of a gene. Each gene has two alleles; humans inherit one allele from mom and one from dad.
Early research suggested that the short alleles predicted unwanted or negative outcomes, such as depression, anxiety and substance abuse. People with short alleles were found to have higher negative emotions than those with long alleles.
But the latest study adds to the growing body of evidence suggesting that people with short alleles also may be more sensitive to the emotional highs of life.
"Having the short allele is not bad or risky," said Haase, an assistant professor in the Human Development and Social Policy program at Northwestern's School of Education and Social Policy. "Instead, the short allele amplifies emotional reactions to both good and bad environments."
"Our study provides a more complete picture of the emotional life of people with the short allele," Haase added. "People with short alleles may flourish in a positive environment and suffer in a negative one, while people with long alleles are less sensitive to environmental conditions."
"The fundamental truth of genes is that they don't have the final say," said senior author Levenson, a leading researcher in human emotions and professor in the department of psychology at UC-Berkeley. "There's always an interaction between nature and nurture that shapes outcomes, and this study is another example of that."
The latest study combined three experiments from different Berkeley labs. In the first experiment, young adults were shown cartoons from "The Far Side" by Gary Larson and The New Yorker. In the second experiment, young, middle-aged and older adults watched a subtly amusing clip from the film "Strangers in Paradise." The final experiment asked middle-aged and older spouses to discuss an area of disagreement in their marriage.
The scientists videotaped the volunteers during the experiments. Trained researchers then coded smiling and laughter using the "Facial Action Coding System," which describes small movements in the face, said Beermann, a postdoctoral researcher at the Swiss Center for Affective Sciences at University of Geneva.
The study focused on genuine or 'real' positive emotional expressions. People sometimes smile or laugh -- even if they don't find something funny -- simply to be polite or to hide negative feelings, Beermann said. "So when you measure smiling and laughing, you want to be able to distinguish real laughs and smiles from the ones that aren't," she said.
The important clues lie in the muscle around the eyes that produce the so-called 'crow's feet,'" Beermann said. "Those can only be seen in real smiles and laughs," she said.
Overall, 336 participants were included in the final analysis. The researchers collected saliva samples from the volunteers to analyze the 5-HTTLPR gene.
The data from the three experiments combined indicated that people with the short allele of 5-HTTLPR showed greater positive emotional expressions. Specifically, people with the short allele displayed greater genuine smiling and laughing than people with the long allele.
"This study provides a dollop of support for the idea that positive emotions are under the same tent as negative ones, when it comes to the short allele," Levenson said. "It may be that across the whole palate of human emotions, these genes turn up the gain of the amplifier. It sheds new light on an important piece of the genetic puzzle."
INFORMATION:
In addition to Haase, Beermann and Levenson, other authors of the paper include Laura Saslow, Osher Center for Integrative Medicine, University of California, San Francisco; Michelle Shiota, department of psychology, Arizona State University; Sarina Saturn, department of psychology, Oregon State University; Patrick Whalen, private practice, Palo Alto; and Sandy Lwi, James Casey, Nguyen K. Nguyen and Dacher Kelter of the department of psychology and the Institute for Personality and Social Research at UC-Berkeley.
VANCOUVER, Wash.--Washington State University researchers have found that the more hunter-gatherers smoke cannabis, the less they are infected by intestinal worms. The link suggests that they may unconsciously be, in effect, smoking medical marijuana.
Ed Hagen, a WSU Vancouver anthropologist, explored cannabis use among the Aka foragers to see if people away from the cultural and media influences of Western civilization might use plant toxins medicinally.
"In the same way we have a taste for salt, we might have a taste for psychoactive plant toxins, because these things ...
Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today*.
Tumours often grow so quickly that some of the cells do not have access to the body's blood supply, causing them to become oxygen-starved. This rapid growth usually sends signals to the cells to die, but in cancers with faults in a gene called p53 -- present in at least half of all cancers -- this signal ...
A debate at this year's Euroanaesthesia meeting in Berlin will focus on whether laughing gas (nitrous oxide) should be banned from the operating room. The debate coincides with an article on the "Current place of nitrous oxide in clinical practice" published in the European Journal of Anaesthesiology, that concludes there is "no clinically relevant evidence for the withdrawal of nitrous oxide from the armamentarium of anaesthesia practice or procedural sedation." The article has been prepared by a special taskforce of the European Society of Anaesthesiology (ESA), which ...
New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally. The study is by Drs Winfried Meissner and Ruth Zaslansky, University Hospital Jena, Germany, and Dr C. Richard Chapman Utah, Pain Research Center, Salt Lake City, USA. All researchers are part of the international PAIN OUT** research group.
Poorly controlled pain after surgery is a major problem internationally ...
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications. The study is reported by Assistant Professor Dr. Robert Sanders, Anesthesiology & Critical care Trials & Interdisciplinary Outcomes Network (ACTION), Department of Anesthesiology, University of Wisconsin, Madison, WN, USA, and Drs. Puja Myles ...
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies.
Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab ...
Using high-precision genetic tests to differentiate the thousands of bacteria that make up the human microbiome, researchers at NYU Langone Medical Center suggest that they have found a possible -- and potentially surprising -- root cause of the increased frequency of certain eye infections among contact lens wearers.
In a study report on their work to be presented at the annual meeting of the American Society for Microbiology on May 31 in New Orleans, NYU Langone researchers say they have identified a diverse set of microorganisms in the eyes of daily contact lens wearers ...
CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each ...
New Haven, Conn. -- Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.
Nearly 300,000 women in the United States are diagnosed with breast cancer each year; more than half undergo breast-conserving surgery with a partial mastectomy to remove the disease. However, between 20% and 40% of patients ...
CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Investigators further found that pacritinib could be used safely in patients with myelofibrosis who ...